These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 37235785

  • 1. EGFR-Targeted Liposomes Combined with Ginsenoside Rh2 Inhibit Triple-Negative Breast Cancer Growth and Metastasis.
    Gu H, Shi R, Xu C, Lv W, Hu X, Xu C, Pan Y, He X, Wu A, Li J.
    Bioconjug Chem; 2023 Jun 21; 34(6):1157-1165. PubMed ID: 37235785
    [Abstract] [Full Text] [Related]

  • 2. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM, Chen G, Wang Y, Hedman CJ, Sherer NM, Havighurst TC, Gong S, Xu W.
    Biomaterials; 2016 Sep 21; 101():20-31. PubMed ID: 27267625
    [Abstract] [Full Text] [Related]

  • 3. Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy.
    Hong C, Wang A, Xia J, Liang J, Zhu Y, Wang D, Zhan H, Feng C, Jiang X, Pan J, Wang J.
    Int J Nanomedicine; 2024 Sep 21; 19():2879-2888. PubMed ID: 38525007
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ginsenoside Rh2 Targets EGFR by Up-Regulation of miR-491 to Enhance Anti-tumor Activity in Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Chen W, Qiu Y.
    Cell Biochem Biophys; 2015 Jun 21; 72(2):325-31. PubMed ID: 25561284
    [Abstract] [Full Text] [Related]

  • 6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS, Ho Y, Lin YW, Naveen Raj E, Liu KK, Chen C, Zhou XZ, Lu KP, Chao JI.
    Acta Biomater; 2019 Mar 01; 86():395-405. PubMed ID: 30660004
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Peptide-functionalized therapeutic nanoplatform for treatment orthotopic triple negative breast cancer and bone metastasis.
    Li D, Ma S, Xu D, Meng X, Lei N, Liu C, Zhao Y, Qi Y, Cheng Z, Wang F.
    Nanomedicine; 2023 Jun 01; 50():102669. PubMed ID: 36933756
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Enhanced anti-glioma activity of annonaceous acetogenins based on a novel liposomal co-delivery system with ginsenoside Rh2.
    Ao H, Song H, Li J, Wang X.
    Drug Deliv; 2024 Dec 01; 31(1):2324716. PubMed ID: 38555735
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
    Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL.
    Mol Cancer Ther; 2014 May 01; 13(5):1356-68. PubMed ID: 24634415
    [Abstract] [Full Text] [Related]

  • 16. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T, Sudhakar G, Marepally S, Patel A, Banerjee R, Singh M.
    Mol Pharm; 2015 Apr 06; 12(4):1105-20. PubMed ID: 25661724
    [Abstract] [Full Text] [Related]

  • 17. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
    Yuan Z, Jiang H, Zhu X, Liu X, Li J.
    Biomed Pharmacother; 2017 May 06; 89():227-232. PubMed ID: 28231544
    [Abstract] [Full Text] [Related]

  • 18. Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis.
    Lev S.
    Biochem Soc Trans; 2020 Apr 29; 48(2):657-665. PubMed ID: 32311020
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR.
    Chan C, Fonge H, Lam K, Reilly RM.
    Nucl Med Biol; 2020 Apr 29; 80-81():37-44. PubMed ID: 31706737
    [Abstract] [Full Text] [Related]

  • 20. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation.
    Cheng L, Huang FZ, Cheng LF, Zhu YQ, Hu Q, Li L, Wei L, Chen DW.
    Int J Nanomedicine; 2014 Apr 29; 9():921-35. PubMed ID: 24611009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.